Asking for support shows self-awareness and commitment to growth. Sandra Lee, Asia CEO at London-based insurer BMS Group Ltd.

Proposed transaction is a reverse takeover transaction with 1317220 B.C. Ltd.Concurrent $10 million equity financing brokered by Clarus ...

Just nine weeks after UnitedHealthcare CEO Brian Thompson was murdered on a weekday morning on a busy street, the luminaries ...

The collaboration has already yielded strong results, including the in-licensing of EVT8683 (now BMS-986419) by Bristol Myers Squibb in September 2021. In March 2023, the companies reaffirmed their ...

But so far, the company is striking out in its attempts to broaden its label. On Thursday, BMS revealed that a phase 3 trial of Opdualag as an adjuvant treatment for patients with completely ...

Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects approximately 112 per 100,000 adults worldwide. It ...

Orally-active mavacamten – which was acquired by BMS when it bought MyoKardia for ... study's main goal compared to 17% of the placebo group. Patients were deemed to have met the treatment ...

Researchers from the University of Chicago Medicine Comprehensive Cancer Center demonstrated the potential of a novel treatment approach including immunotherapy to treat advanced human papillomavirus ...

BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies ...

Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab – was unable to improve on Opdivo alone in the RELATIVITY-098 ...

DelveInsight's "XPOVIO Market Size, Forecast, and Market Insight Report" highlights the details around XPOVIO, a ...